Astellas signs on pluripotent stem cell partners at ExCellThera; Little Unicycive brings home $25M after floating a small IPO
Astellas has signed up on rights for a batch of pluripotent stem cells from Montreal-based ExCellThera, centering on the in vitro use of their UM171 compound.
Astellas is handing over an unspecified upfront payment and promising a slate of milestones to get the collaboration underway.
Guy Sauvageau, CEO and founder of ExCellThera, noted:
While ExCellThera has focused on developing our core strength in other therapeutic areas, Astellas has invested significantly in PSC-related programs and is absolutely the right partner for us in that regard.